| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Catherine K Wang, Gio Kim, Lily R Aleksandrova, William J Panenka, Alasdair M Bar. A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity. Frontiers in pharmacology. vol 15. 2024-06-19. PMID:38887548. |
one of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. |
2024-06-19 |
2024-06-21 |
Not clear |
| FranciscoJ Appiani, Stanley N Carof. The cyclical revival of psychedelics in psychiatric treatment. Current medical research and opinion. 2024-06-16. PMID:38880945. |
over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. |
2024-06-16 |
2024-06-19 |
Not clear |
| Noah Chisamore, Danica Johnson, Margery J Q Chen, Hilary Offman, David Chen-Li, Erica S Kaczmarek, Zoe Doyle, Roger S McIntyre, Joshua D Rosenbla. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. Journal of psychiatric research. vol 176. 2024-06-08. PMID:38850581. |
protocols and practices in psilocybin assisted psychotherapy for depression: a systematic review. |
2024-06-08 |
2024-06-11 |
Not clear |
| Mengyang Xu, Andor J Kiss, J Andrew Jones, Matthew S McMurray, Haifei Sh. Effect of oral tryptamines on the gut microbiome of rats-a preliminary study. PeerJ. vol 12. 2024-06-07. PMID:38846751. |
psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. |
2024-06-07 |
2024-06-10 |
Not clear |
| Laura Ramos, Selene G Vicent. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. Journal of clinical and experimental neuropsychology. 2024-06-06. PMID:38842300. |
the effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. |
2024-06-06 |
2024-06-08 |
Not clear |
| Laura Ramos, Selene G Vicent. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. Journal of clinical and experimental neuropsychology. 2024-06-06. PMID:38842300. |
studying psilocybin effects on cognition and emotional processing may help to clarify the mechanisms underlying the therapeutic potential of psilocybin and may also support studies with people suffering from depression. |
2024-06-06 |
2024-06-08 |
Not clear |
| Qiwen Fang, Vivien Kin Yi Chan, Sandra Sau Man Chan, Yuanshi Jiao, Jiaqi Wang, Xue L. Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis. Psychiatry research. vol 337. 2024-05-23. PMID:38781672. |
efficacy and safety of psilocybin on treatment-resistant depression: a systematic review and meta-analysis. |
2024-05-23 |
2024-05-27 |
Not clear |
| David Nutt, Ilana Crome, Allan H Youn. Is it now time to prepare psychiatry for a psychedelic future? The British journal of psychiatry : the journal of mental science. 2024-05-19. PMID:38764044. |
australia has just rescheduled two drugs controlled under the united nations psychotropic drug conventions, psilocybin and mdma, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. |
2024-05-19 |
2024-05-27 |
Not clear |
| Val Bellma. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730654. |
review of psilocybin use for depression among cancer patients after approval in oregon. |
2024-05-13 |
2024-05-27 |
Not clear |
| Val Bellma. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730654. |
despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through oregon's measure 109 in 2020, significant challenges have impeded its implementation. |
2024-05-13 |
2024-05-27 |
Not clear |
| EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-04. PMID:38704154. |
expression of concern: efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. |
2024-05-04 |
2024-05-07 |
Not clear |
| Claire Parker, Bethany Marie Woo. At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse. Social work. 2024-05-02. PMID:38697188. |
at the forefront: social workers' role in psilocybin treatment for depression and substance misuse. |
2024-05-02 |
2024-05-05 |
Not clear |
| Riccardo De Giorgi, Roger Ed. Psilocybin for depression. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692675. |
psilocybin for depression. |
2024-05-01 |
2024-05-04 |
Not clear |
| Athina-Marina Metaxa, Mike Clark. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692686. |
efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. |
2024-05-01 |
2024-05-04 |
Not clear |
| K Conn, L K Milton, K Huang, H Munguba, J Ruuska, M B Lemus, E Greaves, J Homman-Ludiye, B J Oldfield, C J Fold. Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Molecular psychiatry. 2024-04-27. PMID:38678087. |
psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials for the treatment of anorexia nervosa (an), a condition that is characterised by persistent cognitive inflexibility. |
2024-04-27 |
2024-04-30 |
rat |
| Ram Harari, Ipsita Chatterjee, Dmitriy Getselter, Evan Elliot. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. iScience. vol 27. issue 5. 2024-04-26. PMID:38660396. |
psilocybin has been proposed as a treatment for depression and anxiety but sometimes induces anxiety in humans. |
2024-04-26 |
2024-04-28 |
mouse |
| Gail A Edelsohn, Dominic Sist. Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. Perspectives in biology and medicine. vol 66. issue 1. 2024-04-25. PMID:38662012. |
mdma and psilocybin administered with psychotherapy have received fda designation as "breakthrough therapies" for post-traumatic stress disorder (ptsd) and treatment-resistant depression (trd) respectively. |
2024-04-25 |
2024-04-28 |
Not clear |
| Jordan Sloshower, Richard J Zeifman, Jeffrey Guss, Robert Krause, Hamideh Safi-Aghdam, Surbhi Pathania, Brian Pittman, Deepak Cyril D'Souz. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Scientific reports. vol 14. issue 1. 2024-04-17. PMID:38632313. |
additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin. |
2024-04-17 |
2024-04-20 |
Not clear |
| Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bah. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 2. 2024-04-16. PMID:38627070. |
fda designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (trd) in 2018. |
2024-04-16 |
2024-04-19 |
Not clear |
| Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bah. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 2. 2024-04-16. PMID:38627070. |
this paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. |
2024-04-16 |
2024-04-19 |
Not clear |